Shooting at the DARC: potential issues with species-specific antimalarials

Ian John Woolley, Kylie Horne

Research output: Contribution to journalArticleOtherpeer-review


Scientific drug design enables the production of novel agents that may be specific for individual malaria species, particularly by targeting their methods of cellular entry. Though there are practical and theoretical barriers to introducing novel agents into clinical practice, there may also be theoretical benefits to encourage further investigation of such agents, including a reduction in the rate of development of falciparum resistance. This paper discusses the potential risks and benefits such agents using the example of CCR5 blockers, drugs which are already in use for HIV treatment, but may be able to block DARC, the site of Plasmodium vivax into the human red blood cell.
Original languageEnglish
Pages (from-to)357-359
Number of pages3
JournalInfectious Disorders - Drug Targets
Issue number5
Publication statusPublished - 2012

Cite this